PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer.

IF 1.7 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2025-06-04 DOI:10.1007/s00595-025-03070-6

Ken Onodera, Hirotsugu Notsuda, Sakiko Kumata, Tatsuaki Watanabe, Yui Watanabe, Takaya Suzuki, Takashi Hirama, Hisashi Oishi, Yoshinori Okada

{"title":"PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer.","authors":"Ken Onodera, Hirotsugu Notsuda, Sakiko Kumata, Tatsuaki Watanabe, Yui Watanabe, Takaya Suzuki, Takashi Hirama, Hisashi Oishi, Yoshinori Okada","doi":"10.1007/s00595-025-03070-6","DOIUrl":null,"url":null,"abstract":"Purpose: The expression of PD-L1 is linked to lung cancer severity; however, its prognostic value after resection is unclear. In this study, we investigated its role in resected lung cancers.Methods: We analyzed 658 patients with stage pIA-IIIA NSCLC who underwent complete resection. We assessed the PD-L1 expression by stage and its link to cancer severity, focusing further on its prognostic impact in resected stage I cell lung cancer.Results: The high expression of PD-L1 increased with disease progression (13.0% in IA to 36.2% in III). In stage I non-small cell lung cancer, elevated PD-L1 expression levels were more common in patients with serum CEA levels ≥ 5 (26.0%), SUVmax ≥ 5 (26.7%), and squamous cell carcinoma (41.5%). PD-L1-negative patients showed a better prognosis than PD-L1-positive patients, even with the use of immune checkpoint inhibitors following relapse (5-year OS: 94.3% vs. 83.2%, p < 0.01).Conclusion: The expression of PD-L1 in lung cancer appears to be associated with oncological severity and may influence the prognosis of early-stage disease. Additionally, in early-stage lung cancer, immune checkpoint inhibitors may not fully compensate for the negative prognostic impact of the high expression of PD-L1.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-025-03070-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The expression of PD-L1 is linked to lung cancer severity; however, its prognostic value after resection is unclear. In this study, we investigated its role in resected lung cancers.

Methods: We analyzed 658 patients with stage pIA-IIIA NSCLC who underwent complete resection. We assessed the PD-L1 expression by stage and its link to cancer severity, focusing further on its prognostic impact in resected stage I cell lung cancer.

Results: The high expression of PD-L1 increased with disease progression (13.0% in IA to 36.2% in III). In stage I non-small cell lung cancer, elevated PD-L1 expression levels were more common in patients with serum CEA levels ≥ 5 (26.0%), SUVmax ≥ 5 (26.7%), and squamous cell carcinoma (41.5%). PD-L1-negative patients showed a better prognosis than PD-L1-positive patients, even with the use of immune checkpoint inhibitors following relapse (5-year OS: 94.3% vs. 83.2%, p < 0.01).

Conclusion: The expression of PD-L1 in lung cancer appears to be associated with oncological severity and may influence the prognosis of early-stage disease. Additionally, in early-stage lung cancer, immune checkpoint inhibitors may not fully compensate for the negative prognostic impact of the high expression of PD-L1.

查看原文本刊更多论文

PD-L1表达与早期肺癌的肿瘤严重程度和预后相关。

目的：PD-L1的表达与肺癌严重程度相关；然而，其在切除后的预后价值尚不清楚。在这项研究中，我们研究了它在肺癌切除中的作用。方法：我们分析了658例完全切除的pIA-IIIA期非小细胞肺癌患者。我们评估了分期的PD-L1表达及其与癌症严重程度的关系，并进一步关注其对切除的I期细胞肺癌的预后影响。结果：PD-L1的高表达随着疾病进展而增加（IA为13.0%，III为36.2%）。在I期非小细胞肺癌中，血清CEA≥5（26.0%）、SUVmax≥5（26.7%）和鳞状细胞癌（41.5%）患者中PD-L1表达水平升高更为常见。PD-L1阴性患者的预后优于PD-L1阳性患者，即使在复发后使用免疫检查点抑制剂（5年OS: 94.3% vs. 83.2%, p）。结论：肺癌中PD-L1的表达似乎与肿瘤严重程度有关，可能影响早期疾病的预后。此外，在早期肺癌中，免疫检查点抑制剂可能无法完全补偿PD-L1高表达对预后的负面影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.